Chemokine receptor CXCR4-prognostic factor for gastrointestinal tumors.
To review the implication of CXCR4 for gastrointestinal cancer, a "Pubmed" analysis was performed in order to evaluate the relevance of CXCR4 and its ligands for gastrointestinal cancers. Search terms applied were "cancer, malignoma, esophageal, gastric, colon, colorectal, hepatic, pancreatic, CXCR4, SDF-1alpha, and SDF-1beta". CXCR4 expression correlated with dissemination of diverse gastrointestinal malignomas. The CXCR4 ligand SDF-1alpha might act as "chemorepellent" while SDF-1beta might act as "chemorepellent" for CTLs, inducing tumor rejection. The paracrine expression of SDF-1alpha was furthermore closely associated with neoangiogenesis. CXCR4 and its ligands influence the dissemination, immune rejection, and neoangiogenesis of human gastrointestinal cancers. Inhibition of CXCR4 might be an interesting therapeutic option.
Schimanski
Carl C
CC
First Department of Internal Medicine of Johannes Gutenberg University of Mainz, Mainz 55101, Germany.
Galle
Peter R
PR
Moehler
Markus
M
D000818:Animals; D014408:Biomarkers, Tumor / Q000378:metabolism*; D054377:Chemokine CXCL12 / Q000378:metabolism; D005770:Gastrointestinal Neoplasms / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D006801:Humans; D008024:Ligands; D009361:Neoplasm Invasiveness; D009362:Neoplasm Metastasis; D019718:Receptors, CXCR4 / Q000378:metabolism*; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D054377:Chemokine CXCL12; D008024:Ligands; D019718:Receptors, CXCR4